NEO

Neogenomics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

27.66
-0.88
-3.08%
After Hours: 27.66 0 0.00% 17:14 05/28 EDT
OPEN
28.82
PREV CLOSE
28.54
HIGH
28.82
LOW
27.54
VOLUME
706.60K
TURNOVER
--
52 WEEK HIGH
34.97
52 WEEK LOW
18.52
MARKET CAP
3.04B
P/E (TTM)
869.81
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NEO stock price target is 33.43 with a high estimate of 36.00 and a low estimate of 30.00.

EPS

NEO News

More
NeoGenomics inks deal with Inivata for InVisionFirst-Lung liquid biopsy test
Seeking Alpha - Article · 2d ago
NeoGenomics To Virtually Participate In 17th Annual Craig-Hallum Institutional Investor Conference
FT. MYERS, FL / ACCESSWIRE / May 26, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, today announced that Kathryn McKenzie, Chief Financial Officer ...
ACCESSWIRE · 2d ago
NeoGenomics Enters Strategic Collaboration with Inivata to Commercialize InVisionFirst(R)-Lung Liquid Biopsy Test
FORT MYERS, FL / ACCESSWIRE / May 26, 2020 / NeoGenomics, Inc. (NEO) (the "Company"), a leading provider of cancer-focused genetics testing services, announced today that it has formed a strategic collaboration with Inivata to commercialize the InVisionFirst-L
ACCESSWIRE · 2d ago
Edited Transcript of NEO earnings conference call or presentation 28-Apr-20 12:30pm GMT
Thomson Reuters StreetEvents · 05/18 17:25
NeoGenomics To Virtually Participate In Fireside Chat At BofA Securities 2020 Health Care Conference
FT. MYERS, FL / ACCESSWIRE / May 11, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, today announced that Doug VanOort, Chairman and Chief Executive ...
ACCESSWIRE · 05/11 20:05
2 Stocks to Buy and Hold for Decades
MotleyFool.com · 05/09 15:47
NeoGenomics and Bayer Collaborate to Offer NTRK Testing for Certain Colorectal and Thyroid Cancer Patients
ACCESSWIRE · 05/05 13:00
Here's Why NeoGenomics Is Tumbling Today
Motley Fool · 04/30 17:07

Industry

Healthcare Facilities & Services
-2.41%
Healthcare Providers & Services
-0.46%

Hot Stocks

Symbol
Price
%Change

About NEO

NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.
More

Webull offers kinds of NeoGenomics, Inc. stock information, including NASDAQ:NEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NEO stock news, and many more online research tools to help you make informed decisions.